Related Experiment Video
Updated: Aug 10, 2026
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Comparative clinical efficacy and safety of netilmicin and tobramycin in children with serious gram-negative
Abstract:
Thirty children with serious gram-negative infections were treated with either netilmicin, 2 mg/kg, or tobramycin, 1 mg/kg, every eight hours for a minimum of 72 hours. Because of the administration of different doses, a "blind" investigator evaluated treatment response while another investigator adjusted the doses on the basis of each patient's drug serum levels and bacteriological response. Comparisons between the two study groups showed both treatments to be equally effective. All 15 patients treated with netilmicin and 14 of the 15 patients treated with tobramycin experienced complete resolution of clinical signs and symptoms and elimination of pathogens. One child in the tobramycin group was considered a treatment failure because of a persistent urinary tract infection. There were no adverse effects attributable to either drug.
Insights
Netilmicin and tobramycin showed equal effectiveness in treating serious gram-negative infections in children. Both antibiotics achieved high clinical resolution rates with no significant adverse effects observed in this comparative study.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Serious gram-negative infections pose a significant threat to pediatric patients.
- Aminoglycosides like netilmicin and tobramycin are crucial in treating such infections.
- Optimizing treatment efficacy and safety is essential for pediatric care.
Purpose of the Study:
- To compare the efficacy and safety of netilmicin versus tobramycin in treating serious gram-negative infections in children.
- To evaluate clinical resolution, pathogen elimination, and adverse effects of both antibiotics.
Main Methods:
- A comparative study involving 30 children with serious gram-negative infections.
- Patients were treated with either netilmicin (2 mg/kg) or tobramycin (1 mg/kg) every eight hours for at least 72 hours.
- A blinded investigator assessed treatment response, while doses were adjusted based on serum levels and bacteriological outcomes.
Main Results:
- Both netilmicin and tobramycin demonstrated comparable efficacy.
- Complete clinical resolution and pathogen elimination were observed in 15/15 netilmicin patients and 14/15 tobramycin patients.
- One tobramycin patient experienced treatment failure due to a persistent urinary tract infection; no adverse effects were reported for either drug.
Conclusions:
- Netilmicin and tobramycin are equally effective for treating serious gram-negative infections in children.
- Both antibiotics exhibit a favorable safety profile in the pediatric population.
- Further research may explore optimal dosing strategies for specific gram-negative pathogens in children.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:25Clinical Significance of Antibiotic Resistance